Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 998 results for death

  1. Neutropenic sepsis: prevention and management in people with cancer (CG151)

    This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

  2. Percutaneous retroperitoneal endoscopic necrosectomy (HTG255)

    Evidence-based recommendations on percutaneous retroperitoneal endoscopic necrosectomy. This involves inserting a thin telescope through a small cut in the side above the hip and using it to wash out and remove the dead tissue.

  3. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.

  4. Asthma: annual review (higher risk patients) (IND315)

    This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  5. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  6. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

  7. Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)

    Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.

  8. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

  9. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  10. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  11. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

  12. Families and relationships settings

    moderate learning disability and is experiencing depression after her father's death. Her mum, Shazia, is overwhelmed as she also cares...

  13. Coronary revascularisation: Cangrelor (ESNM63)

    Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making